Scitop develops and sells edible probiotics and microecological preparations, and its products serve food, health care, animal husbandry, and agriculture.
Beijing Scitop Bio-tech Co’s stock price drops to **13.70 CNY**, a **2.35% decline** from its prior close of **14.03 CNY** in Thursday’s trading session. The company operates in the biotechnology sector within the Chinese market. The decline reflects short-term market fluctuations without additional context on underlying drivers.
Oct 2026Global Banking & Finance ReviewNews article
Beijing Scitop Bio-tech Co reports a **39% decline in net profit** despite revenue growth, as expenses from new production capacity exceed sales gains. The company’s financial performance highlights challenges in scaling operations efficiently. Analysts note the mismatch between increased output and cost management.
Beijing Scitop Bio-tech Co reports a **20.85% revenue increase**, driven by growth in probiotics and microecological agents. The company maintains stable net profit despite rising sales. These specialized products appear central to its financial performance.
Beijing Scitop Bio-Tech, a leading Chinese probiotics company, plans to allocate most of its IPO proceeds toward expansion. The firm is preparing to list on the Shenzhen Stock Exchange, signaling growth ambitions in the probiotics sector.
